Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio
German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from...
Lonza
Innovent Biologics’ CLDN18.2-Targeted ADC IBI343 Earns FDA Fast-Track Status
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Innovent Biologics’ CLDN18.2 ADC IBI343 Receives Breakthrough Designation in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Lonza Announces Factory Closures in the US and China Amid Global Network Optimization
Swiss Contract Manufacturing Organization (CMO) Lonza has released its 2023 financial report, which includes plans...
Innovent Biologics Expands Partnership with Synaffix for New ADC Development
Innovent Biologics Inc. (HKG: 1801) has announced an expanded partnership with U.S.-based Synaffix B.V., a...